Gaurav Munj 2022-03-04T06:42:16+00:00 CREATING SHAREHOLDER VALUE Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases September 28, 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 August 26, 2026 Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy View All Press Releases View All Events May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases September 28, 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 August 26, 2026 Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy View All Press Releases View All Events May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management May 27, 2026 at 9:45 AM EDT Biohaven R&D Day 2026 at Yale School of Management January 12, 2026 at 8:15 AM PST 44th Annual J.P. Morgan Healthcare Conference View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEOUntitled Document VIDEOSplay videoINTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEYx play videoInterview with CEO Vlad Coric M.D. on CNBC’s Mad Moneyxplay videoDiseases related to glutamate dysregulationx
September 28, 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
August 26, 2026 Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy